Cas9 activates the p53 pathway and selects for p53-inactivating mutationsOana M. Enache, Uri Ben‐David, Desiree Davison et al.|Nature Genetics|2020Cited by 285
A window-of-opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastomaVerónica Rendo, Rameen Beroukhim, Eudocia Q. Lee et al.|Science Translational Medicine|2025Cited by 13